Siren Biotechnology and Catalent to Manufacture AAV Gene Therapies for Cancer
Siren Biotechnology has signed a strategic partnership with Catalent to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies.
Siren Biotechnology | 18/05/2024 | By Aishwarya | 259
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy